N-8-(2-chlorophenyl)-N-2-(2,6-difluorophenyl)-9-ethyl-9H-purine-2,8-diamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: N-8-(2-chlorophenyl)-N-2-(2,6-difluorophenyl)-9-ethyl-9H-purine-2,8-diamine
• 英文别名: 8-(2-Chlorophenylamino)-2-(2,6-difluorophenylamino)-9-ethyl-9H-purine-1,7-diium；8-N-(2-chlorophenyl)-2-N-(2,6-difluorophenyl)-9-ethylpurine-2,8-diamine
• 化学式: C₁₉H₁₅ClF₂N₆
• 分子量: 400.818
• InChiKey: ZWKOUFZHPNIQSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  67.7
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,6-二氟苯胺 在 palladium on activated charcoal 氢气 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 3.75h， 生成 N-8-(2-chlorophenyl)-N-2-(2,6-difluorophenyl)-9-ethyl-9H-purine-2,8-diamine
  参考文献：
  名称：

  The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-α production

  摘要：

  A series of C-2, C-8, and N-9 trisubstituted purine based inhibitors of TNF-alpha production are described. The most potent analogs showed low nanomolar activity against LPS-induced TNF-alpha production in a THP-1 cell based assay. The SAR of the series was optimized with the aid of X-ray co-crystal structures of these inhibitors bound with mutated p38 (mp38).

  DOI：

  10.1016/j.bmcl.2006.05.050

文献信息

• Purine cytokine inhibitors
  申请人：The Procter & Gamble Company

  公开号：US07256196B1

  公开（公告）日：2007-08-14

  The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,8,9-substituted purines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

  本发明涉及抑制炎症细胞因子的细胞外释放的2,8,9-取代嘌呤，这些细胞因子负责一个或多个人类或更高级哺乳动物的疾病状态。本发明还涉及包含所述2,8,9-取代嘌呤的组合物以及用于预防、减轻或以其他方式控制被认为是负责所述疾病状态的活性成分的酶的方法。
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• US7256196B1
  申请人：——

  公开号：US7256196B1

  公开（公告）日：2007-08-14